Chimeric Antigen Receptor T Cell (CAR-T) Therapy
Customize your policy alerts
Sign up for univerahealthcare Policy PHARMACY-103 alerts
Get alerted when Policy PHARMACY-103 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization, coverage criteria, and utilization management for FDA-approved CAR-T cellular therapies administered under Univera Healthcare medical/pharmacy benefits across specified lines of business.
No material clinical or coverage changes in this revision.
Coverage Criteria
Abecma (idecabtagene vicleucel) — Initial Therapy
Abecma (idecabtagene vicleucel) is covered when ALL of the following are met:
HCPCS Q2055 applies
Abecma (idecabtagene vicleucel) Initial Therapy (duplicate)
Abecma — Covered when ALL of the following are met
HCPCS Q2055
Gene/Cellular Therapy Restrictions — general limits applicable to CAR-T
General gene and cellular therapy limits (applies to CAR-T unless specified otherwise):
Includes increased risks such as immune activation, insertional mutagenesis, or vector immunity.
Includes switching between CAR-T products, switching between autologous and allogeneic therapies, and receiving in vivo gene therapy after prior vector exposure.
Aucatzyl (obecabtagene autoleucel) — Initial Therapy
Aucatzyl — Covered when ALL of the following are met
HCPCS Q2058
Breyanzi (lisocabtagene maraleucel) — Initial Therapy
Breyanzi — Covered when ALL of the following are met (product covers multiple lymphoma/CLL/FL/MCL/MZL indications with condition-specific nodes)
Breyanzi will not be approved for primary central nervous system lymphoma. HCPCS Q2054
Carvykti (ciltacabtagene autoleucel) — Initial Therapy
Carvykti — Covered when ALL of the following are met
HCPCS Q2056
Kymriah (tisagenlecleucel) — Initial Therapy
Kymriah — Covered when ALL of the following are met (pediatric/young adult ALL or specific lymphoma indications)
Kymriah will not be approved for primary central nervous system lymphoma.
HCPCS Q2042
Tecartus (brexucabtagene autoleucel) — Initial Therapy
Tecartus — Covered when ALL of the following are met
HCPCS Q2053
Yescarta (axicabtagene ciloleucel) — Initial Therapy
Yescarta — Covered when ALL of the following are met
HCPCS Q2041
Coverage for CAR-T therapies is subject to the member's specific contract and benefit language. Utilization management is contract dependent; exclusion or limitation of drug coverage may be determined by contract renewal date, specific subscriber exclusions, or whether a given contract covers healthcare-professional-administered drugs under the pharmacy or medical benefit. Providers should verify member benefits before initiating authorization.
Aucatzyl (obecabtagene autoleucel) is not covered for members who have received prior anti-CD19 therapy other than blinatumomab. Requests for Aucatzyl will be denied when there is documented prior exposure to anti-CD19 agents other than blinatumomab.
Breyanzi (lisocabtagene maraleucel) and Kymriah (tisagenlecleucel) are not approved for primary central nervous system lymphoma. Requests with a primary CNS lymphoma diagnosis will not be approved.
When an accelerated-approval indication has been withdrawn by the FDA, coverage for that indication will only be considered for patients who were already established on the therapy prior to the FDA withdrawal date listed on the FDA website. Providers and patients should consult regarding continuation when an approval is withdrawn.
Retreatment, reinfusion, or sequential administration of the same or additional gene/cellular therapies is considered experimental/investigational and therefore not medically necessary absent supporting evidence. This policy applies to repeat dosing of the same product and to switching between different gene/cellular products (including between CAR-T constructs or between autologous and allogeneic approaches) unless there is clear evidence documenting anticipated benefit and safety.
Initial Therapy Criteria (Product-specific)
Abecma (idecabtagene vicleucel) Initial Therapy — product-specific initial criteria
Abecma-specific initial criteria (product-specific details)
HCPCS Q2055
Initial therapy requirements (general)
Product-specific initial coverage criteria require prescriber specialty, age, diagnosis, measurable disease/biopsy confirmation, and prior lines of therapy as specified:
See individual product nodes for exact requirements.
Initial therapy example (Yescarta)
Initial therapy requirement example (Yescarta):
HCPCS Q2041
Continuation and Supportive Therapy Criteria
Tocilizumab concurrent approval — supportive drug approval associated with CAR-T authorization
Supportive drug approval associated with CAR-T authorization
Applies across listed CAR-T products
Tocilizumab approval with Yescarta
Concomitant biologic approval when CAR-T is approved (Yescarta-specific):
Prior authorization required for Yescarta regardless of site of administration; HCPCS Q2041 applies.
Provider Actions and Documentation Requirements
Prior authorization required for CAR-T therapies
Prior authorization is required for CAR-T therapies; approvals are generally issued for a 6-month period and apply regardless of inpatient or outpatient site of administration.
PA required for each CAR-T product (all sites)
Prior authorization must be obtained for each CAR-T product listed in this policy and applies regardless of the site of administration (inpatient or outpatient).
Potential step therapy and evidence basis
Step therapy may be imposed in addition to LCD/NCD requirements; prior authorization criteria are based on the FDA label or NCCN level 1/2A evidence and specific step requirements depend on the drug and contract.
Prior lines and documented failure required
Most CAR-T products require prior lines of systemic therapy (typically two or more) with documented failure or refractoriness to specified classes before approval.
- Documented failure or refractoriness to agents such as anti-CD38, proteasome inhibitors, immunomodulatory agents, anthracyclines, CD20-targeted agents, BTK inhibitors, or TKIs where applicable.
Yescarta first-line therapy requirement
For Yescarta, the patient must have received adequate first-line therapy including an anthracycline and a CD20-targeted agent (e.g., a rituximab-containing product) prior to approval.
Submit clinical documentation with each request
Clinical documentation must be submitted for each request (initial and recertification) and include progress notes, prior treatments, diagnostic testing, laboratory results, genetic/biomarker results, imaging, and other objective or subjective measures of clinical benefit.
Abecma-specific documentation elements
For Abecma requests, provide documentation confirming the prescribing clinician is a Hematologist or Oncologist, patient age ≥18, diagnosis of relapsed/refractory multiple myeloma, measurable disease per specified lab thresholds, and prior lines of therapy including an anti-CD38, a proteasome inhibitor, and an immunomodulatory agent.
- Measurable disease thresholds: serum M-protein ≥1.0 g/dL; urine M-protein ≥200 mg/24 h; involved FLC ≥10 mg/dL with abnormal ratio
- Prior therapies must include anti-CD38 mAb, proteasome inhibitor, and immunomodulatory agent
Required clinical documentation (prescriber, diagnosis, prior treatments)
Provide evidence of prescriber specialty (Hematologist or Oncologist), documentation of diagnosis, prior treatment lines and failures, and demonstration of measurable disease or biopsy confirmation as specified per product.
Tocilizumab automatically approved with Yescarta (6 months)
Patients approved for Yescarta will also receive approval for tocilizumab for a period of 6 months; if severe or life‑threatening cytokine‑release syndrome is suspected, administer tocilizumab per weight‑based dosing guidance.
- Tocilizumab dosing: 12 mg/kg IV over 1 hour for patients <30 kg; 8 mg/kg IV over 1 hour for patients ≥30 kg
- Tocilizumab approval duration: 6 months
Coverage dependent on member contract/benefits
Utilization management, coverage criteria, and drug coverage are contract dependent; refer to the member's contract/benefit language as exclusions or noncoverage may apply and affect approvals.
Retreatment or sequential gene/cellular therapy is non‑approved
Retreatment with the same gene/cellular therapy or treatment with an additional/sequential gene or cellular therapy after prior exposure is considered experimental/investigational and is not eligible absent supportive evidence.
- Includes switching between CAR-T products or between autologous and allogeneic approaches
- Prior exposure to any autologous/allogeneic cellular therapy, in‑vivo gene therapy, or ex‑vivo gene‑modified product generally precludes additional therapy unless evidence supports safety and benefit
Aucatzyl prior anti‑CD19 therapy exclusion
Aucatzyl will not be approved if the patient has received prior anti‑CD19 therapy other than blinatumomab.
Primary CNS lymphoma exclusion
Breyanzi and Kymriah will not be approved for a diagnosis of primary central nervous system lymphoma.
Reimbursement depends on subscriber contract (codes may not be covered)
Eligibility for reimbursement and code coverage is determined by the member's subscriber contract; HCPCS codes cited in this policy may not be covered under all contracts or circumstances.
Coding and HCPCS Mapping
| Q2055 | HCPCS code cited for Abecma |
| Q2055 | HCPCS for Abecma |
| Q2058 | HCPCS for Aucatzyl |
| Q2054 | HCPCS for Breyanzi |
| Q2056 | HCPCS for Carvykti |
| Q2042 | HCPCS for Kymriah |
| Q2053 | HCPCS for Tecartus |
| Q2041 | HCPCS for Yescarta |
Step Therapy Requirements
| Requirement | Notes |
|---|---|
| Step therapy may be imposed in addition to LCD/NCD requirements | |
| Prior authorization criteria are based on the FDA-labeled indication or NCCN level 1 or 2A evidence |
| Requirement | Example product(s) / detail |
|---|---|
| Members must have received the specified prior lines and classes of systemic therapy | |
| Examples: for multiple myeloma products (Abecma, Carvykti) documented prior lines include anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent; for lymphoma products, prior anthracycline and a CD20-targeted agent are frequently required | |
| Documented failure or refractoriness to specified agents or classes as detailed in product-specific criteria is required |
| Yescarta prior therapy requirement | Policy detail |
|---|---|
| Patient must have received adequate first-line therapy including an anthracycline and a CD20-targeted agent | |
| Examples: prior regimen must include a rituximab-containing product in combination with an anthracycline per Yescarta criteria; prior authorization applies regardless of site of administration |
Site of Care and Setting
PA applies regardless of site; site may affect timeframe
Prior authorization applies regardless of the site of administration (inpatient, outpatient, or infusion center); the requested site of care may impact the approval timeframe and is subject to review.
PA applies to inpatient and outpatient settings
Prior authorization is required for CAR‑T products regardless of whether administration is inpatient or outpatient.
Yescarta PA required for inpatient or outpatient use
Prior authorization for Yescarta is required irrespective of the site of administration (inpatient or outpatient).
Background
Chimeric antigen receptor T‑cell (CAR‑T) therapy is an adoptive cellular therapy in which a patient’s T cells are genetically engineered to recognize and destroy target cells. Multiple FDA‑approved CAR‑T products target antigens such as CD19 or BCMA and are indicated for specific hematologic malignancies including relapsed or refractory multiple myeloma, B‑cell precursor acute lymphoblastic leukemia, diffuse large B‑cell and related large B‑cell lymphomas, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and CLL/SLL. These therapies have generally been developed and studied as one‑time administrations; repeat dosing or sequential gene/cellular interventions have not been established as safe or effective and are treated as investigational unless supported by evidence.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.